Jane Street
CRVS icon

Jane Street’s Corvus Pharmaceuticals CRVS Stock Holding History

Jane Street’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-44,473
Closed -$617K – 11765
2026
Q1 		$651K Sell
44,473
-333,824
-88% -$5.33M ﹤0.01% 7424
2025
Q4 		$2.91M Buy
378,297
+310,231
+456% +$2.45M ﹤0.01% 4097
2025
Q3 		$502K Buy
68,066
+57,948
+573% +$297K ﹤0.01% 7856
2025
Q2 		$40.5K Sell
10,118
-247,685
-96% -$901K ﹤0.01% 9226
2025
Q1 		$820K Buy
257,803
+142,851
+124% +$673K ﹤0.01% 5943
2024
Q4 		$615K Buy
114,952
+64,731
+129% +$483K ﹤0.01% 6336
2024
Q3 		$265K Buy
+50,221
New +$180K ﹤0.01% 8227
2024
Q1 		– Sell
-23,095
Closed -$40.6K – 9310
2023
Q4 		$40.6K Buy
+23,095
New +$33.8K ﹤0.01% 8822
2023
Q3 		– Sell
-35,118
Closed -$80.4K – 8730
2023
Q2 		$80.4K Buy
+35,118
New +$73K ﹤0.01% 8082
2022
Q4 		– Sell
-20,775
Closed -$17K – 9271
2022
Q3 		$17K Buy
+20,775
New +$19.8K ﹤0.01% 9241
2021
Q4 		– Sell
-173,937
Closed -$675K – 10154
2021
Q3 		$842K Buy
+173,937
New +$515K ﹤0.01% 6255

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Jane Street's CRVS Position: Q2 2026 in Review

Jane Street sold out of Corvus Pharmaceuticals (CRVS) in Q2 2026, closing a stake of 44,473 shares — an estimated $617K sold.

Jane Street first reported a position in CRVS in Q3 2021 and held it in 11 quarters. The position peaked at $2.91M in Q4 2025. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Jane Street reported no remaining Corvus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 44,473 Corvus Pharmaceuticals shares in Q2 2026, an estimated $617K.
  • Jane Street first reported a position in Corvus Pharmaceuticals in Q3 2021 and held it in 11 quarters.
  • Jane Street's Corvus Pharmaceuticals position peaked at $2.91M in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.